Florida's Public Cannabis Companies Are Reporting Q3. Verano's Release Mentions Florida Once.
SNDL, Verano, Curaleaf, Green Thumb, Trulieve, Cresco and Vireo have reported, and only Vireo put a number on Florida. Planet 13 and iAnthus haven't set a date. Here is the calendar, and what the filings and calls say about Florida.
NY 420 Week · 13 November 2026 · Update to "Nine Public Companies Sell 72% of Florida's Medical Cannabis"
Nine publicly traded companies ran dispensaries in Florida until 9 November, when Vireo completed its purchase of FLUENT; a tenth has an indirect stake in one. In the state's newest weekly table, for 6–12 November, the listed companies' stores ran 531 of Florida's 791 dispensaries and dispensed 73.4% of the state's THC, counting FLUENT's own sales up to 9 November.
Seven companies with Florida exposure have now reported third-quarter results. Only Vireo said what Florida earned it.
The calendar
| Company | Ticker | Florida brand | Florida stores | Q3 results | Call (ET) |
|---|---|---|---|---|---|
| SNDL (indirect stake in Surterra) | NASDAQ: SNDL | Surterra | 43 | Reported 27 Oct | 27 Oct |
| Verano | Cboe CA / OTCQX: VRNO | MÜV | 88 | Reported 29 Oct | 29 Oct, 8:30 a.m. |
| Curaleaf | TSX: CURA · OTCQX: CURLF | Curaleaf | 80 | Reported 3 Nov | 3 Nov, 5:00 p.m. |
| Green Thumb | CSE: GTII · OTCQX: GTBIF | Rise | 27 | Reported 4 Nov | 4 Nov, 5:00 p.m. |
| Trulieve | NYSE: TRLV | Trulieve | 171 | Reported 5 Nov | 5 Nov, 8:30 a.m. |
| Cresco Labs | CSE: CL · OTCQX: CRLBF | Sunnyside | 31 | Reported 6 Nov | 6 Nov, 8:30 a.m. |
| Vireo Growth | CSE: VREO · OTCQX: VREOF | Green Dragon | 74 | Reported 10 Nov | 10 Nov, 8:00 a.m. |
| FLUENT Corp. (acquired by Vireo 9 Nov) | CSE: FNT.U · OTCQB: CNTMF | FLUENT | — (now Green Dragon) | — | — |
| Planet 13 | CSE: PLTH · OTCQX: PLNH | Planet 13 | 34 | Not announced | — |
| iAnthus | CSE: IAN · OTC: ITHUF | GrowHealthy | 26 | Not announced | — |
Florida store counts are the state's, for the week of 6–12 November 2026; Green Dragon's 74 include FLUENT's former stores. Dates are from each company's own announcement: SNDL, Verano, Curaleaf, Green Thumb, Trulieve, Cresco, Vireo.
Verano: one Florida sentence, then an 87th store
Verano's third-quarter release, out on 29 October, reported revenue of $212.4 million, up 5% from $202.8 million a year earlier. Gross margin held at 47%. The net loss narrowed to $4.1 million from $43.8 million, adjusted EBITDA was $50.4 million (24% of revenue), and the company ended September with $102 million of cash and $390 million of debt.
Florida appears once, as a highlight: "Expanded Florida retail footprint with the opening of MÜV Bradfordville, the Company's 86th Florida dispensary and 163rd location nationwide." There is no Florida revenue figure and no other Florida commentary in the release. A week later Verano opened MÜV Fernandina Beach on 6 November, its 87th Florida store. The state's table for 6–12 November lists 88 MÜV stores; we have not found a company announcement of an 88th. MÜV dispensed 11.8% of Florida's THC that week. Verano's quarterly report adds one Florida dollar item: a $3.6 million impairment on a Florida cultivation facility it had listed for sale. It then "determined the facility no longer met the criteria to be classified as held-for-sale," and moved it back onto its books at $10.9 million.
The call said more. Founder and chief executive George Archos said Florida's medical program "approaches 1 million registered patients," that several more MÜV stores are due to open by year-end, and that "we will see a big uptick in Florida, if the hemp ban goes into effect in December." Asked about adult use, he said: "Florida, I don't personally believe that AU is on the short-term horizon."
SNDL: closer to Surterra, still not consolidated
SNDL doesn't own Surterra's 43 Florida stores directly; they sit in a creditor vehicle in which SNDL has an indirect stake. Its third-quarter release says a rights offering raised that indirect equity ownership "from approximately 67% to 92%," and that SNDL also financed the purchase of more of Parallel's debt, "increasing SunStream's debt ownership from 39.4% to 69.4%."
SNDL "continues to evaluate a pathway to directly own and consolidate Parallel's U.S. medical cannabis operations." It has not done so yet, so Surterra's Florida results are still not in SNDL's numbers. The release says SNDL-funded investment in "a new cultivation facility in Gainesville, Florida" is "expected to enhance Parallel's cost structure"; the carrying value of that investment rose C$70.0 million in the quarter, partly to fund the Gainesville build-out.
SNDL's own quarter: net revenue of C$238.0 million, down 2.5%, and a net loss of C$50.8 million that includes a C$52 million goodwill impairment in its cannabis operations. The release gives no Florida store count and no Surterra revenue.
Curaleaf: record revenue, two Florida store counts
Curaleaf reported after the close on 3 November. Revenue was $352.7 million, up 10.9% from $317.9 million, which the company called a record. Gross margin slipped 2.2 points to 48.3%. Adjusted EBITDA was $77.6 million, 22.0% of revenue, and the net loss attributable to the company was $32.7 million. It ended September with $104.9 million of cash and $636.9 million of debt.
Florida comes up twice, both times as a store count. In the quarter, Curaleaf "expanded retail footprint in Florida to 78 with two new dispensary openings in Port Richey and Riverview." After the quarter, it reached 80 with the Port Orange and Wellington openings, which matches the state's table for 6–12 November. There is no Florida revenue figure in the release. It also says Curaleaf began receiving DEA registrations for medical dispensaries after the quarter, without naming the states.
On the call, president Rahul Pinto said sequential domestic growth was "led by Florida, Ohio, Maine, and Pennsylvania." Chairman and chief executive Boris Jordan, asked about Florida, said: "We intend to end the year at around 89, 90 stores in Florida." He said the company started the year "I think, at 65"; the state's table for 26 December – 1 January lists 69. He said Curaleaf's same-store sales in Florida are up year over year, without a figure, and that "the state is starting to get a bit saturated," so store openings "will slow down."
The release has an update on Curaleaf's hostile bid for Aurora Cannabis, too. Earlier filings showed Curaleaf raising the offer to US$1.00 in cash plus 0.4013 Curaleaf shares per Aurora share and Aurora's board rejecting it again. Now the release says Aurora has announced an alternative deal to merge with Organigram, and that Curaleaf is evaluating that deal and its options. On the call, Jordan went further: "Curaleaf is going to improve our bid substantially. We will have to get due diligence in Aurora." Separately, an October 8-K disclosed a one-time grant of 1,344,275 restricted stock units and a $1 million discretionary bonus for chairman and chief executive Boris Jordan.
Vireo: the only Florida number so far, and FLUENT closes
Vireo reported before the open on 10 November. Revenue was $253.7 million, up from $91.7 million a year earlier, mostly because of acquisitions. GAAP gross margin was 42.5%, the net loss was $24.0 million, and adjusted EBITDA was $42.7 million, a 16.8% margin. It ended September with $106.8 million of cash and $293 million of long-term debt.
Its state-by-state table is the first this round to put a dollar figure on Florida: retail revenue of $12.7 million in the quarter, up from $9.5 million in the second quarter, its first full quarter in the state. On a pro forma basis Vireo puts the year-ago figure at $7.0 million, an 81% increase. The table has no Florida wholesale line. On the call, according to the transcript Vireo filed with the SEC,, analyst Pablo Zuanic of Zuanic & Associates noted Florida was "up 34% quarter-on-quarter." Chief executive John Mazarakis answered: "I think we're properly scaled in Florida and you should expect that similar growth across the board for the quarters to come."
On 2 November, Vireo said the DEA had issued federal registrations for all 41 of its Florida medical dispensaries, which the release describes as among the first issued to state-licensed medical dispensaries under the Schedule III framework in the DEA's April 2026 rule. Chief executive John Mazarakis: "Florida is one of our key markets, and we are pleased to have received these registrations." The release doesn't say what the registrations mean for Vireo's taxes or its numbers.
On 21 October it filed a transcript of an interview Sam Armenia, Vireo's director of capital markets, gave on 19 October. In it he said of Florida, citing the state's own weekly data: "Green Dragon, which is our business there, is number one in absolute growth year over year for Q3."
That claim covers July through September. The state's weekly tables for October show a different trend: Green Dragon's weekly THC fell from 21.4 million milligrams in the week of 2–8 October to 14.7 million in the week of 16–22 October, a drop of 31% in three weeks, from the same 41 stores. It ticked back up to 15.2 million in the week of 23–29 October and 16.0 million in the week of 30 October – 5 November. In the week of 6–12 November, with FLUENT's stores now counted under Green Dragon, the 74 stores dispensed 27.1 million.
The FLUENT deal is now done. FLUENT, whose shareholders approved its merger into Vireo on 28 July, said on 2 November it plans to convert about US$5.7 million of senior secured debt into 310,194,363 shares, closing "immediately prior" to the Vireo deal. On 4 November it amended its credit agreement: its lenders consented to the Vireo deal and lent another US$10.5 million. Vireo completed the acquisition on 9 November, which it says gives it "approximately 74 operational dispensaries" in Florida. The state's table for 6–12 November already lists Green Dragon with 74 stores and shows FLUENT's own sales only through 9 November; together they dispensed 9.4% of Florida's THC that week.
For Planet 13, Vireo filed the final proxy statement/prospectus on 2 November; Vireo's results release says the registration statement became effective that day. Planet 13's shareholders vote on the merger at a virtual special meeting on 10 December; holders of record on 29 October can vote. With Planet 13's 34 stores, Vireo would run 108 in Florida. In the October interview, Armenia described Florida growth "assuming we close the other two deals."
Green Thumb: 27 Florida stores and a "particularly strong" mention
Green Thumb reported after the close on 4 November. Revenue was $324.4 million, up 11.3% from $291.4 million. Gross margin was 45.2%, or 50.1% before $15.8 million of RYTHM brand licensing fees. The company swung to a $4.8 million net loss from $23.3 million of net income a year earlier. Adjusted EBITDA was $73.7 million, and it ended September with $316.0 million of cash and $277.3 million of debt.
Florida shows up four times, more than in any release so far, but still without a dollar figure. Two of the six Rise stores opened in the quarter were in Port Charlotte and Port St. Lucie. Since then, Cape Coral, Belleview and Mulberry have taken it to 27 Florida locations, matching the state's table for 6–12 November. Florida is listed with New Jersey, New York, Ohio and Virginia as markets where growth was "particularly strong," and president Anthony Georgiadis said Florida accounted for five of the nine new stores. The release says some of its medical dispensaries have received DEA registrations, without naming the states; on the call, chief executive Ben Kovler said "certain medical licenses now registered in Florida and Virginia and others pending." Georgiadis said: "In Florida, despite persistent competition and pricing pressure, we've materially improved four-wall economics across the platform." He said three to five more Florida stores will open by year-end.
Trulieve: revenue down 20%, and Florida without a number
Trulieve reported before the open on 5 November. Revenue was $230.2 million, down about 20% from $288.2 million. Gross margin rose to 64% from 59%, and the company earned $0.9 million for shareholders after losing $26.8 million a year earlier. Adjusted EBITDA was $89.2 million, a 39% margin. It ended September with $326.7 million of cash, and operations brought in $74.4 million in the quarter.
Trulieve is still Florida's biggest seller by far: 171 stores and 28.4% of the state's THC in the week of 6–12 November. In the release, Florida comes up as a store opening in Marco Island, the early repayment of $65 million of mortgage notes secured by its Jefferson County cultivation site, and a perpetual, royalty-free license for Alien Labs and Connected products in Florida and Texas; its quarterly report puts the license's cost at $40.4 million, for both states together. There is no Florida revenue figure. Its investor presentation does have a Florida page: "Flower market share 34%," and 943,844 patients in the state as of 30 October. In the state's data for 6–12 November, Trulieve's share of smokable flower was 34.8%. Trulieve also said it received final DEA registrations under the Schedule III order, and that it now runs 208 dispensaries.
On the call, chief executive Kimberly Rivers gave Florida volumes but not dollars: "Trulieve sold 55% more flower per store than the state average, across 170 stores, totaling 657 thousand ounces." The state's data backs that up. Over the 13 weekly tables from 3 July to 1 October, Trulieve dispensed 656,762 ounces of smokable flower, 54.8% more per store than the state average. Rivers also said that, compared with the second quarter, an additional 200 patients a week were being added to the state's registry, and that Florida "held a little bit better" than its usual third-quarter seasonal pattern.
Cresco: not in the release, one line in the MD&A
Cresco reported before the open on 6 November. Revenue was $172.8 million, up about 5% from $164.9 million. Gross margin was 46.0%, the net loss was $14.5 million, and adjusted EBITDA was $34.9 million, a 20.2% margin. It ended September with $76 million of cash and $454 million of long-term notes and loans, and operations brought in $26.1 million.
The word Florida doesn't appear in the release. Cresco runs 31 Sunnyside stores in the state, according to the state's table for 6–12 November, but the release only says it "operates highly productive dispensaries nationally under the Sunnyside brand." It also doesn't mention DEA registrations or Schedule III. Florida does appear once in the management's discussion filed the same day: nine-month revenue was hurt by "increased competition and price compression" in several markets, including the "Florida retail market."
On the call, Florida came up only when an analyst asked about it. Chief executive Charles Bachtell said rivals had built extra capacity preparing for adult use in 2024, and that Florida "is a state that you'll see us continue to evaluate for further investment."
iAnthus: quiet
We found nothing from iAnthus since its second-quarter report in August, and no third-quarter results as of 12 November.
What to listen for
Last quarter only two of the nine — FLUENT and Vireo — put a dollar figure on what Florida earned them. This round only Vireo has: $12.7 million. Otherwise, Verano has added one store count, SNDL a construction project, Curaleaf two store counts, Green Thumb a store count and a "particularly strong," Trulieve a store opening, a debt payoff, a brand license and a flower share, and Cresco one line in its MD&A. On the calls, executives said more about Florida than their releases did: store targets, a patient count, a flower claim the state's data confirms. None of the others gave a Florida revenue figure. Planet 13's shareholders vote on its sale to Vireo on 10 December; Planet 13 and iAnthus still haven't set results dates. The state's data will keep arriving every Friday regardless.
Methodology: Florida store counts and weekly THC are from the Florida Office of Medical Marijuana Use weekly updates of 9, 16, 23 and 30 October and 6 and 13 November 2026; each table was checked against the state's printed totals. The share of THC and store count for the listed chains (including FLUENT's sales through 9 November, as the state reports them), and the MÜV and Trulieve shares, are for the week of 6–12 November. Company figures are from each company's own release or quarterly report; SNDL reports in Canadian dollars. Call quotes are from published third-party transcripts (Motley Fool for Trulieve; Quartr via StockAnalysis for Curaleaf and Verano; Earnings Whispers for Green Thumb and Cresco; Vireo's own transcript, filed with the SEC), which we have not checked against the audio. Trulieve's flower comparison uses the state's weekly updates of 10 July to 2 October 2026. Earnings dates are from each company's announcement; for Verano we used a published copy of the company release. SEC filings were located by search because EDGAR's index pages were unavailable to us, so small filings may be missing. Florida does not publish dollar sales. This is not investment advice. Updated 13 November 2026, with the state's data for 6–12 November.